K140702
Page 1 of 6

APR 0 4 2014

EIZO Corporation, 153 Shimokashiwano, Hakusan, Ishikawa
924-8566 Japan

Name Hiroaki Hashimoto
Department Medical System Standards

Telephone +81 (76) 274-2468
Fax +81 (76) 274-2484
E-Mail hiroaki.hashimoto@eizo.com

U.S. Food and Drug Administration
Center for Devices and Radiological Health
Document Mail Center – WO66-G609
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

510(k) Summary (in accordance with 21 CFR 807.92)

1. Company

EIZO Corporation
153 Shimokashiwano, Hakusan
Ishikawa 924-8566 Japan
Tel: +81 (76) 274-2468
Fax: +81 (76) 274-2484

2. Contact Person

Hiroaki Hashimoto

3. Date of Summary

March 18th, 2014

4. Device Information

- Trade Name/Model: RadiForce RX850
- Common Name: 8MP Color LCD Monitor
- Classification Name: Display, Diagnostic Radiology
- Product Code: PGY
- Regulation Number: 21 CFR 892.2050

5. Predicate Device

- 8MP Color LCD Monitor, RadiForce RX840-MG (K120451)

6. Device Description

RadiForce RX850 is a color LCD monitor for viewing medical images including those of mammography. The color panel employs in-plane switching (IPS) technology allowing wide viewing angles. With the matrix size (or resolution) of 4,096 x 2,160 pixels (8MP), the RX850 is an alternate replacement for traditional dual head 5MP display installations.



RadiForce RX850



5MP Monochrome Monitors

Since factory calibrated display modes, each of which is characterized by a specific tone curve (including DICOM GSDF), a specific luminance range and a specific color temperature, are stored in lookup tables within the monitor, the tone curve is e.g. DICOM compliant regardless of the display controller used.

RadiCS is application software to be installed in each workstation offering worry-free quality control of the diagnostic monitors including the RadiForce RX850 based on the QC standards and guidelines and is capable of quantitative tests and visual tests defined by them. The RadiCS and its subset, RadiCS LE, are included in this 510(k) submission as an accessory to the RadiForce RX850.

7. Intended Use

This product is intended to be used in displaying and viewing digital images including those of digital mammography for review and analysis by trained medical practitioners.

8. Comparison of Technological Characteristics

The comparison table below enumerates information derived from the product brochure of the each device and different technological characteristics are discussed in it:

Attributes	RadiForce RX850	RadiForce RX840-MG	Explanation of Differences
Display Performance/Specifications			
Screen technology	IPS TFT Color LCD	IPS TFT Color LCD	-
Viewing angle (H, V)	H: 178°, V: 178°	H: 176°, V: 176°	Eizo uses typical data for very low contrast provided by the panel manufacturers.
Resolution	8MP (4,096 x 2,160)	8MP (4,096 x 2,160)	-
Aspect ratio	17 : 9	17 : 9	
Active screen size	697.9 mm x 368.0 mm	817.1 mm x 430.9 mm	The smaller pixel pitch or pixel size means higher density usually resulting in higher quality of displayed images. If one cares about the smaller pixel size, the perceived pixel size similar to that of the predicate device can be realized easily by adjusting the viewing distance.
Pixel pitch	0.1704 mm x 0.1704 mm	0.1995 x 0.1995 mm	
Maximum luminance	850 cd/m^2	700 cd/m^2	-
DICOM calibrated luminance	500 cd/m^2	500 cd/m^2	-
Contrast ratio	1450 : 1	1000 : 1	Eizo uses typical contrast ratio data provided by panel manufacturers.
Backlighting	LED	LED	-
Display Colors	From a palette of 68 billion colors: - 10-bit input (DisplayPort): 1.07 billion colors (maximum) - 8-bit input: 16.77 million colors	From a palette of 68 billion colors: - 10-bit input (DisplayPort): 1.07 billion colors (maximum) - 8-bit input: 16.77 million colors	-
Luminance non-uniformity compensation	Digital Uniformity Equalizer	Digital Uniformity Equalizer	-

Video Signal Input			
Input video signals	DVI-D (dual link) x 2, DisplayPort x 2 (two inputs are required)	DVI-D (dual link) x 2, DisplayPort x 2	-
Scanning Frequency (H, V)	31 - 140 kHz / 59 - 61 Hz (VGA Text: 69 - 71 Hz) Frame synchronous mode: 29.5 - 30.5 Hz, 59 - 61 Hz	31 - 140 kHz / 29.5 - 30.5 Hz only for 2,048 x 2,160 and 1,920 x 2,160, 59 - 61 Hz for other matrix sizes (VGA Text: 69 - 71 Hz) Frame synchronous mode: 29.5 - 30.5 Hz, 59 - 61 Hz	-
Power Related Specifications			
Power Requirements	AC 100 - 120 V, 200 - 240 V: 50 / 60 Hz	AC 100 - 120 V, 200 - 240 V: 50 / 60 Hz	-
Power Consumption / Save Mode	227 W / Less than 6 W	350 W / Less than 6 W	The proposed device consumes less power than the predicate device.
Power Management	DVI DMPM, DisplayPort 1.1a	DVI DMPM, DisplayPort 1.1a	-
Miscellaneous Features/Specifications			
QC software	RadiCS	RadiCS	-
Sensors	Backlight Sensor, Integrated Front Sensor, Presence Sensor, Ambient Light Sensor	Backlight Sensor, Integrated Front Sensor, Presence Sensor, Ambient Light Sensor	-
USB Ports / Standard	1 upstream, 2 downstream / Rev. 2.0	1 upstream, 2 downstream / Rev. 2.0	-
Dimensions w/o stand (W x H x D)	747 x 430 x 130 mm	896 x 527 x 157 mm	Different housing design due to the different panel size.

It is clear that the technological characteristics differences discussed above do not affect the safety and the effectiveness of the RX850.

9. Performance Testing

The bench tests below were performed on the RadiForce RX850 following the instructions in *Guidance for Industry and FDA Staff: Display Accessories for Full-Field Digital Mammography Systems-Premarket Notification (510(k)) Submissions*:

- Verification of the conformance to DICOM GSDF as specified in *Assessment of Display Performance for Medical Imaging Systems* by AAPM Task Group 18 (TG18 guideline)
- Measurement of the angular dependency of luminance response in horizontal, vertical and diagonal directions
- Measurement of the luminance non-uniformity characteristics of the display screen as specified in TG18 guideline
- Measurement of the chromaticity non-uniformity characteristics of the display screen as specified in TG18 guideline
- Measurement of the chromaticity at the center of the display screen at 5%, 50% and 95% of the maximum luminance
- Measurement of display reflections including specular, diffuse and haze components
- Measurement of small-spot contrast ratio
- Measurement of spatial resolution expressed as modulation transfer function (MTF)
- Measurement of noise expressed as noise power spectrum (NPS)
- Measurement of pixel aperture ratio
- Visual check of presence or absence of miscellaneous artifacts on the display screen as specified in TG18 guideline
- Measurement of temporal response
- Performance data on luminance stability
- The maximum number allowed for each type of pixel defects/faults

The test results showed that the RadiForce RX850 has display characteristics equivalent to those of the predicate device, RadiForce RX840-MG except 2 items, each of which was determined that it would not affect observer's performance.

Besides, the display characteristics of the RadiForce RX850 meet the pre-defined criteria when criteria are set.

No animal or clinical testing was performed on the RadiForce RX850.

10. Conclusion

The RadiForce RX850 was determined to be substantially equivalent to the predicate device due to the following reasons:

- The stated intended use is completely the same as that of the predicate device.
- It was confirmed that the technological characteristics differences from those of the predicate device do not affect the safety or the effectiveness.
- The bench tests demonstrated that the display characteristics are equivalent to those of the predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

April 4, 2014

EIZO Corporation
% Mr. Hiroaki Hashimoto
153 Shimokashiwano, Hakusan
ISHIKAWA 924-8566
JAPAN

Re: K140702
Trade/Device Name: 8MP Color LCD Monitor, RadiForce RX850
Regulation Number: 21 CFR 892.2050
Regulation Name: Picture archiving and communications systems
Regulatory Class: II
Product Code: PGY
Dated: March 18, 2014
Received: March 20, 2014

Dear Mr. Hashimoto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

for

Janine M. Morris
Director, Division of Radiological Health
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*
K140702

Device Name
8MP Color LCD Monitor, RadiForce RX850

Indications for Use *(Describe)*
This product is intended to be used in displaying and viewing digital images including those of digital mammography for review and analysis by trained medical practitioners.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) *(Signature)*



This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."